Leuprolide

Therapeutic

Palliative treatment of advanced prostate cancer and treatment of pediatric patients with central precocious puberty (CPP), initial treatment of the symptoms of endometriosis.

Structural features

SMILES

CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1

Sequence

XHWSYlLRP-NHEt

Molar mass

1209.421 g/mol

Constitutional members:

9

Natural amino acids

7

D-Amino acids

1

N-terminus

pyroglutamyl

C-terminus

NHEt

Cyclic

no

Members/cycle

N.A.

Bond to form cycle

N.A.

Lipidation

no

Glycosylation

no

Route of administration

SC, IM, TOPICAL

Terminal half-life

Leuprolide has a terminal elimination half-life of approximately 3 hours

Protein binding

43-49%

Absorption and Bioavailability

Bioavailability by subcutaneous administration is comparable to that of intravenous administration

References